PR

Privia Health Group, Inc.

PRVAHealthcareNASDAQ

Health Information Services · Last scanned Sep 8, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.12B
+22.3% YoY
Net Income
$22.9M
+59.3% YoY
EBITDA
$44.1M
+82.0% YoY
Free Cash Flow
$95.6M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OversoldRSI 28.1, below 30, stock may be oversold
Sep 2 MACD Positive CrossoverHistogram +0.0212, positive momentum
About Privia Health Group, Inc.

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. With a market capitalization of $2.64B, it sits in mid-cap territory. The company collaborates with physician practices, health plans, and health systems.

Where PRVA stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, PRVA finished 10.34% below its 150-day moving average ($23.11) and 10.96% below its 200-day moving average ($23.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is PRVA overbought or oversold?

At the September 3, 2026 close, PRVA's RSI(14) was 28.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.64B
P/E (TTM)93.91
Fwd P/E19.43
EPS$0.22
Beta0.88
52W Change-11.8%
ROE4.3%
Analysis

With $412.2M in cash and $8.7M in debt, PRVA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $95.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 4.3%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.36B (2022) to $2.12B (2025), reflecting a 56% increase over the period.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, PRVA carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Privia Health Group, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms